Mean Platelet Volume and Cancer-Associated Deep Vein Thrombosis

Background: Deep vein thrombosis (DVT) is a common and serious complication in cancer patients, primarily driven by malignancy-induced hypercoagulability and systemic inflammation. Mean platelet volume (MPV), a hematological parameter reflecting platelet activation and inflammatory status, has been proposed as a potential marker for thromboembolic risk stratification in oncology. Objective: This retrospective study aimed to assess the association between MPV and DVT in patients with underlying cancer. Methods: We analyzed MPV levels in a cohort of 102 patients diagnosed with DVT, including 18 individuals with active malignancy. Results: Although MPV values were slightly elevated in cancer patients compared to non-cancer patients, the difference did not reach statistical significance (p = 0.86). Conclusion: Our findings suggest that MPV is not a reliable biomarker for cancer-associated DVT. Further studies exploring alternative hematological and inflammatory markers are warranted to improve risk assessment in this high-risk population.